Change in 
TSS
As a double‐blind, head‐to‐head comparison of two active JAK inhibitors, momelotinib versus ruxolitinib, a prespecified objective of SIMPLIFY‐1 was to demonstrate non‐inferiority for TSS response at Week 24. In SIMPLIFY‐2, the open‐label comparison of momelotinib to BAT in previously JAK inhibitor‐treated patients, a prespecified objective was to demonstrate superiority for TSS at Week 24.Here, the method for deriving the between‐groups non‐inferiority margin in SIMPLIFY‐1 considers the preserved fraction of the variability closest to estimating a null effect MPN‐SAF TSS change score. In this case, the upper bound of the 95% CI for the overall change score in the population at Week 24 is preserved. Results were presented for preserved fractions of 50%, 75%, and 90%. To support this interpretation, the magnitude of the effect size differences in MPN‐SAF TSS was presented using Cohen's The within‐patient‐group non‐inferiority margin for SIMPLIFY‐1 in this study used two metrics: (1) the anchor‐based meaningful change threshold (MCT) derived using treatment agnostic trial data